Endothelial Toll-like receptor 4 is required for microglia activation in the murine retina after systemic lipopolysaccharide exposure.
Endothelial cells
Lipopolysaccharide
Microglia
Monocyte-derived macrophages
Retina
Toll-like receptor 4
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
04 Feb 2023
04 Feb 2023
Historique:
received:
01
07
2022
accepted:
30
01
2023
entrez:
4
2
2023
pubmed:
5
2
2023
medline:
8
2
2023
Statut:
epublish
Résumé
Clustering of microglia around the vasculature has been reported in the retina and the brain after systemic administration of lipopolysaccharides (LPS) in mice. LPS acts via activation of Toll-like receptor 4 (TRL4), which is expressed in several cell types including microglia, monocytes and vascular endothelial cells. The purpose of this study was to investigate the effect of systemic LPS in the pigmented mouse retina and the involvement of endothelial TLR4 in LPS-induced retinal microglia activation. C57BL/6J, conditional knockout mice that lack Tlr4 expression selectively on endothelial cells (Tek Activation of microglia, infiltration of monocyte-derived macrophages, impaired ribbon synapse organization and retinal dysfunction were observed after the LPS exposure in C57BL/6J and Tek The findings of the present study suggest that systemic LPS exposure can have detrimental effects in the healthy retina and that TLR4 expressed on endothelial cells is essential for retinal microglia activation and retinal dysfunction upon systemic LPS challenge. This important finding provides new insights into the role of microglia-endothelial cell interaction in inflammatory retinal disease.
Sections du résumé
BACKGROUND
BACKGROUND
Clustering of microglia around the vasculature has been reported in the retina and the brain after systemic administration of lipopolysaccharides (LPS) in mice. LPS acts via activation of Toll-like receptor 4 (TRL4), which is expressed in several cell types including microglia, monocytes and vascular endothelial cells. The purpose of this study was to investigate the effect of systemic LPS in the pigmented mouse retina and the involvement of endothelial TLR4 in LPS-induced retinal microglia activation.
METHODS
METHODS
C57BL/6J, conditional knockout mice that lack Tlr4 expression selectively on endothelial cells (Tek
RESULTS
RESULTS
Activation of microglia, infiltration of monocyte-derived macrophages, impaired ribbon synapse organization and retinal dysfunction were observed after the LPS exposure in C57BL/6J and Tek
CONCLUSIONS
CONCLUSIONS
The findings of the present study suggest that systemic LPS exposure can have detrimental effects in the healthy retina and that TLR4 expressed on endothelial cells is essential for retinal microglia activation and retinal dysfunction upon systemic LPS challenge. This important finding provides new insights into the role of microglia-endothelial cell interaction in inflammatory retinal disease.
Identifiants
pubmed: 36739425
doi: 10.1186/s12974-023-02712-1
pii: 10.1186/s12974-023-02712-1
pmc: PMC9899393
doi:
Substances chimiques
Lipopolysaccharides
0
Toll-Like Receptor 4
0
Tlr4 protein, mouse
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25Informations de copyright
© 2023. The Author(s).
Références
Nat Rev Immunol. 2003 Feb;3(2):169-76
pubmed: 12563300
J Neurochem. 2017 Oct;143(2):198-213
pubmed: 28792619
J Neurochem. 2012 Jul;122(2):392-403
pubmed: 22536982
Curr Protoc Mouse Biol. 2012 Sep 01;2(3):207-18
pubmed: 26069012
Br J Haematol. 2001 Mar;112(4):1041-7
pubmed: 11298604
J Neurosci. 2012 Aug 22;32(34):11706-15
pubmed: 22915113
Eur J Biochem. 1997 Apr 15;245(2):215-32
pubmed: 9151947
Exp Eye Res. 2015 Sep;138:114-23
pubmed: 26091789
Cell Death Dis. 2018 Mar 2;9(3):350
pubmed: 29500424
Mol Neurobiol. 2019 Feb;56(2):976-985
pubmed: 29855971
J Neurosci. 2011 Nov 9;31(45):16241-50
pubmed: 22072675
Science. 2011 Sep 9;333(6048):1456-8
pubmed: 21778362
Front Immunol. 2019 May 24;10:1169
pubmed: 31178871
Am J Pathol. 2002 Feb;160(2):501-9
pubmed: 11839570
J Immunol. 1995 May 1;154(9):4309-21
pubmed: 7722289
Front Immunol. 2018 Sep 03;9:1939
pubmed: 30233570
Nat Neurosci. 2016 Mar;19(3):504-16
pubmed: 26780511
Cytometry A. 2010 Nov;77(11):1082-90
pubmed: 20824631
J Vis Exp. 2018 Jun 5;(136):
pubmed: 29939190
Oncotarget. 2017 May 9;8(19):31638-31654
pubmed: 28404943
PLoS One. 2012;7(7):e39890
pubmed: 22802947
Mediators Inflamm. 2013;2013:124614
pubmed: 23864765
Front Cell Neurosci. 2018 Dec 13;12:494
pubmed: 30618641
Front Immunol. 2019 Apr 26;10:912
pubmed: 31105708
Eur J Neurosci. 2001 Nov;14(10):1651-8
pubmed: 11860459
Invest Ophthalmol Vis Sci. 2011 Jul 29;52(8):5824-35
pubmed: 21666244
Neurotoxicology. 2018 Mar;65:98-110
pubmed: 29427613
Nat Neurosci. 2018 Oct;21(10):1359-1369
pubmed: 30258234
Invest Ophthalmol Vis Sci. 2013 Dec 17;54(13):8125-39
pubmed: 24204040
Immunity. 2019 Mar 19;50(3):723-737.e7
pubmed: 30850344
J Neuroinflammation. 2018 Dec 12;15(1):340
pubmed: 30541565
Lab Anim. 2015 Apr;49(1 Suppl):37-46
pubmed: 25835737
J Hematol Oncol. 2013 Aug 22;6:61
pubmed: 23965413
J Neurosci. 2016 Mar 02;36(9):2827-42
pubmed: 26937019
Cell. 1994 Jan 28;76(2):301-14
pubmed: 7507411
Immunology. 2010 Apr;129(4):556-66
pubmed: 20102413
Ann N Y Acad Sci. 2008 Oct;1139:318-30
pubmed: 18991877
J Neuroinflammation. 2012 Jun 27;9:146
pubmed: 22738332
FEBS J. 2022 Apr;289(8):2337-2361
pubmed: 34478598
Circulation. 2007 Mar 27;115(12):1599-608
pubmed: 17372179
Pharmacol Res. 2021 Dec;174:105877
pubmed: 34610452
Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3058-63
pubmed: 9096345
J Leukoc Biol. 2017 May;101(5):1119-1132
pubmed: 28196850
Lab Invest. 2006 Jan;86(1):9-22
pubmed: 16357866
J Neuroimmunol. 2007 Oct;190(1-2):101-11
pubmed: 17884182
Acta Neuropathol. 2010 Jan;119(1):89-105
pubmed: 20012873
J Immunol. 2006 Dec 1;177(11):8103-10
pubmed: 17114485
J Cell Sci. 2003 Dec 1;116(Pt 23):4695-705
pubmed: 14600256
Nat Rev Immunol. 2007 Sep;7(9):678-89
pubmed: 17717539
PLoS One. 2012;7(5):e36560
pubmed: 22615780
Inflammation. 2019 Apr;42(2):440-448
pubmed: 30645708
Curr Opin Ophthalmol. 2004 Dec;15(6):519-30
pubmed: 15523198
Nat Commun. 2019 Dec 20;10(1):5816
pubmed: 31862977
J Immunol. 2008 Mar 15;180(6):3789-96
pubmed: 18322185
Toxicology. 2004 Sep 1;201(1-3):197-207
pubmed: 15297033
J Clin Invest. 2020 Apr 1;130(4):1977-1990
pubmed: 32149735
Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7438-42
pubmed: 1651506
Eur J Ophthalmol. 2011;21 Suppl 6:S3-9
pubmed: 23264323
Neurotoxicology. 2020 Mar;77:181-192
pubmed: 32014511
PLoS One. 2018 Jan 5;13(1):e0190546
pubmed: 29304053
Brain Behav Immun. 2010 Jan;24(1):102-9
pubmed: 19735725
Middle East Afr J Ophthalmol. 2012 Jan;19(1):52-9
pubmed: 22346115
J Neuroimmunol. 2004 Aug;153(1-2):7-15
pubmed: 15265658
J Neuroinflammation. 2016 Mar 12;13(1):64
pubmed: 26970737
J Immunol. 2009 Oct 15;183(8):5244-50
pubmed: 19786543
Transl Vis Sci Technol. 2016 Aug 18;5(4):11
pubmed: 27570710